Ines El Naggar

Ines El Naggar

Auto-generated profile, based on publicly available information

Ines El Naggar

Department of Pediatric Neurology, Vestische Kinder-und Jugendklinik Datteln, University of Witten-Herdecke, Datteln, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2022 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
AMAdela Della Marina
Adela Della Marina
ABAnnikki Bertolini
Annikki Bertolini
AWAndreas Wegener-Panzer
Andreas Wegener-Panzer
MFMarina Flotats-Bastardas
Marina Flotats-Bastardas
TRTabea Reinhardt
Tabea Reinhardt
KRKevin Rostasy
Kevin Rostasy

22 July 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
INInes El Naggar
Ines El Naggar
RCRobert Cleaveland
Robert Cleaveland
EWEva-Maria Wendel
Eva-Maria Wendel
ABAnnikki Bertolini
Annikki Bertolini
KSKathrin Schanda
Kathrin Schanda
GWGert Wiegand
Gert Wiegand

24 January 2025 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
FKFranziska Kauth
Franziska Kauth
ABAnnikki Bertolini
Annikki Bertolini
EWEva-Maria Wendel
Eva-Maria Wendel
GKGeorgia Koukou
Georgia Koukou
INInes El Naggar
Ines El Naggar
KRKevin Rostasy
Kevin Rostasy

17 August 2024 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
MJMaike Josler
Maike Josler
INInes El Naggar
Ines El Naggar
ABAnnikki Bertolini
Annikki Bertolini
PKPatrizia Kutz
Patrizia Kutz
CRClaudia Roll
Claudia Roll
KRKevin Rostasy
Kevin Rostasy

1 September 2025 in Neurology Open Access
Verified
Journal Article
Closed access
JKJoseph Kuchling
Joseph Kuchling
GKGeorgia Koukou
Georgia Koukou
FBFrederik Bartels
Frederik Bartels
RCRobert Cleaveland
Robert Cleaveland
AWAndreas Wegener-Panzer
Andreas Wegener-Panzer
CFCarsten Finke
Carsten Finke

1 January 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
JMJason Millward
Jason Millward
EPElias Pilgrim
Elias Pilgrim
MBMatthias Baumann
Matthias Baumann
EWEva-Maria Wendel
Eva-Maria Wendel
INInes El Naggar
Ines El Naggar
SWSonia Waiczies
Sonia Waiczies
Pediatric patients with acute disseminated encephalomyelitis (ADEM) are at risk of impaired brain growth, with long-term neuropsychiatric consequences. We previously reported transient expansions of cerebral ventricle volume (VV) in experimental autoimmune encephalomyelitis, which subsequently normalized. In this study, we investigated changes in VV in ADEM in relation to other brain structures and clinical outcomes. We investigated brain MRI scans acquired in routine clinical practice from a multicenter cohort of 61 pediatric patients with ADEM, of whom 39 were myelin oligodendrocyte glycoprotein (MOG) antibody-positive. Patients were compared with 1,219 pediatric healthy controls (HCs). Volumes of multiple brain structures were computed using a contrast-agnostic machine learning-based tool and analyzed with mixed-effect models regarding other clinical parameters. Patients with ADEM had larger VV than HCs at initial clinical presentation, before immune therapy. Most of the patients showed further VV increases within 2 months after disease onset. Patients had smaller brain volumes than HCs, with specific reductions in deep gray matter structures. These changes were more pronounced in MOG antibody-negative patients.Of the patients with more than 2 MRI scans, 12 of 22 resolved their VV expansion back to within 15% of baseline values while 10 of 22 had persistently increased VV at the last available MRI within 1 year from onset. Patients with persistent VV expansion had greater reductions in volumes of other brain structures at the last MRI than patients whose VV resolved and were more likely to have residual neurologic signs. The VV resolving and nonresolving patients did not differ regarding age, sex, elevated CSF cell counts at baseline, or occurrence of relapses. However, patients with a larger magnitude of VV expansion-≥90% of baseline volume-were more likely to be in the nonresolving group. We could distinguish between 2 outcomes of VV changes in ADEM: one in which the VV expanded but ultimately returned to normal and one in which the expansions continued after disease onset and treatment but failed to resolve. The latter was associated with reduced brain volume, particularly in deep gray matter structures. This highlights the necessity for patients with ADEM to undergo regular MRI scans to assess whether developing VV expansions indicate a greater risk of permanent brain atrophy.